Krystal Biotech Inc (KRYS) Stock Price, Quote & News

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 586 5830

Website: www.krystalbio.com

Address:

2100 Wharton Street, Suite 701, Pittsburgh, United States

Cutlass Jun. 22 at 12:50 PM

$KRYS Ahh the good old days in the 30's and 40's - I sold out awhile back - 💥

0 · Reply

Florestan Jun. 21 at 2:39 AM

$KRYS the king of gene therapy. Undisputed.

0 · Reply

WAJeff Jun. 18 at 6:42 PM

$KRYS $356.50 ath

0 · Reply

LewisDaKat Jun. 18 at 10:30 AM

$KRYS These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead https://marketwirenews.com/stock/krys/news/these-3-stocks-have-crushed-the-market-this-year-her-4537015809779451.html?utm_source=stocktwits

0 · Reply

WAJeff Jun. 17 at 3:17 PM

$KRYS $340.79 ath

0 · Reply

SwingTraderPro1 Jun. 11 at 10:26 PM

TODAY’S MARKET READ Seeing some solid pin action from my long book. Still holding index shorts, but longs are clearly outperforming on a relative basis. Long exposure includes: $ASML $VIK $MATX $ROST $KRYS Most of these were positioned ahead of the recent pullback, and they’re now doing the heavy lifting. Net: cautious macro view, but stock-picking alpha is still working. Watching how this divergence plays out into the close.

0 · Reply

WAJeff Jun. 11 at 4:05 PM

$KRYS $325 ath

0 · Reply

ZManicItalian Jun. 9 at 9:29 PM

$KRYS

0 · Reply

Shlobby May. 14 at 2:10 PM

Long $KRYS

0 · Reply

CapitalMonk May. 13 at 4:25 AM

$KRYS Price: $310.31 (-0.82%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.00% RSI: 70.1 | Momentum: Strong Momentum Volume: +3.1% vs avg Volatility: 2.58% Support: $251.97 | Resistance: $315.17 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

Krystal Biotech price target raised to $403 from $306 at TD Cowen

2026-06-16T13:08:12.000Z - 8 days ago

Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright

May 21, 2026, 8:00 AM EDT - 4 weeks ago

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

CRBP

May 20, 2026, 7:00 AM EDT - 5 weeks ago

Krystal Biotech Slides: Corporate presentation

2026-05-18T12:17:39.000Z - 5 weeks ago

Krystal Biotech announces UK MHRA approval of Vyjuvek

May 18, 2026, 8:00 AM EDT - 5 weeks ago

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

May 15, 2026, 4:00 PM EDT - 5 weeks ago

Krystal Biotech Transcript: AGM 2026

2026-05-15T18:26:55.000Z - 5 weeks ago

U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

May 13, 2026, 2:20 PM EDT - 6 weeks ago

Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

2026-05-05T12:35:28.000Z - 7 weeks ago

Krystal Biotech price target raised to $300 from $295 at Evercore ISI

2026-05-05T10:40:32.000Z - 7 weeks ago

Krystal Biotech price target raised to $378 from $371 at Citi

2026-05-04T16:07:40.000Z - 7 weeks ago

Krystal Biotech price target lowered to $311 from $338 at Clear Street

May 4, 2026, 8:30 AM EDT - 7 weeks ago

Krystal Biotech Earnings Call Transcript: Q1 2026

May 4, 2026, 8:30 AM EDT - 7 weeks ago

Krystal Biotech Earnings release: Q1 2026

May 4, 2026, 8:30 AM EDT - 7 weeks ago

Krystal Biotech Quarterly report: Q1 2026

May 4, 2026, 8:30 AM EDT - 7 weeks ago

Krystal Biotech Slides: Q1 2026

2026-05-04T11:15:40.000Z - 7 weeks ago

Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M

2026-05-04T11:06:39.000Z - 7 weeks ago

Krystal Biotech reports Q1 EPS $1.83, consensus $1.42

May 4, 2026, 7:00 AM EDT - 7 weeks ago

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech Proxy statement: Proxy filing

2026-03-26T20:23:32.000Z - 3 months ago

Krystal Biotech initiated with a Peer Perform at Wolfe Research

2026-03-24T11:35:21.000Z - 3 months ago

Krystal Biotech price target raised to $325 from $318 at BofA

Mar 4, 2026, 6:00 AM EST - 4 months ago

Krystal Biotech Slides: Corporate presentation

Mar 3, 2026, 3:10 PM EST - 4 months ago

Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T12:03:05.000Z - 4 months ago

Krystal Biotech price target raised to $284 from $224 at Guggenheim

2026-02-18T13:01:08.000Z - 4 months ago

Krystal Biotech price target raised to $323 from $220 at Chardan

2026-02-18T11:11:02.000Z - 4 months ago

Krystal Biotech price target raised to $371 from $336 at Citi

2026-02-17T18:35:39.000Z - 4 months ago

Krystal Biotech price target raised to $371 from $310 at Jefferies

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Annual report: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Earnings release: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Slides: Q4 2025

2026-02-17T12:11:57.000Z - 4 months ago

Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M

2026-02-17T12:05:09.000Z - 4 months ago

Krystal Biotech reports Q4 EPS $1.70, consensus $1.61

Feb 17, 2026, 7:00 AM EST - 4 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 8:00 AM EST - 4 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

2026-02-09T13:11:11.000Z - 4 months ago

Krystal Biotech granted RMAT designation for KB707 in NSCLC

2026-01-30T12:37:18.000Z - 5 months ago

Krystal Biotech price target raised to $327 from $206 at Goldman Sachs

2026-01-26T11:05:06.000Z - 5 months ago

Krystal Biotech price target raised to $338 from $288 at Clear Street

Jan 15, 2026, 10:31 AM EST - 5 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Jan 12, 2026, 10:30 AM EST - 5 months ago

Krystal Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 5 months ago

Krystal Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 1:00 PM EST - 5 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:30 PM EST - 5 months ago

Krystal Biotech Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 5 months ago

Krystal Biotech Press release: Study Update

Jan 8, 2026, 4:30 PM EST - 5 months ago

Krystal Biotech Slides: Study Update

Dec 3, 2025, 10:00 AM EST - 7 months ago

Krystal Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 8:00 AM EST - 7 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Slides: Q3 2025

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Sep 4, 2025, 10:20 AM EDT - 10 months ago

Krystal Biotech Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 12:11 PM EDT - 10 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Slides: Q2 2025

Jul 25, 2025, 9:00 AM EDT - 11 months ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 24, 2025, 4:30 PM EDT - 11 months ago

Krystal Biotech Transcript: Study Result

Jul 24, 2025, 4:30 PM EDT - 11 months ago

Krystal Biotech Press release: Study Result

Jul 24, 2025, 4:30 PM EDT - 11 months ago

Krystal Biotech Slides: Study Result

Jul 24, 2025, 8:00 AM EDT - 11 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Transcript: Study Update

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Press release: Study Update

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Slides: Study Update

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Krystal Biotech Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 14, 2025, 2:20 PM EDT - 1 year ago

Krystal Biotech Transcript: BofA Securities 2025 Healthcare Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Slides: Q1 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech Proxy statement: Proxy Filing

Mar 4, 2025, 1:50 PM EST - 1 year ago

Krystal Biotech Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 7:40 AM EST - 1 year ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Annual report: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings release: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jan 14, 2025, 8:00 AM EST - 1 year ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Transcript: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Press release: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Status Update

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Dec 4, 2024, 2:10 PM EST - 1 year ago

Krystal Biotech Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 8:45 AM EST - 1 year ago

Krystal Biotech Transcript: Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 18, 2024, 10:55 AM EST - 1 year ago

Krystal Biotech Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 1:30 PM EST - 1 year ago

Krystal Biotech Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Quarterly report: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings release: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Q3 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Krystal Biotech Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 4:30 PM EDT - 1 year ago

Krystal Biotech Transcript: Study Result

Aug 28, 2024, 4:30 PM EDT - 1 year ago

Krystal Biotech Press release: Study Result

Aug 28, 2024, 4:30 PM EDT - 1 year ago

Krystal Biotech Slides: Study Result

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings Call Transcript: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Quarterly report: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings release: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Slides: Q2 2024

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Jun 11, 2024, 10:40 AM EDT - 2 years ago

Krystal Biotech Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 14, 2024, 5:20 PM EDT - 2 years ago

Krystal Biotech Transcript: BofA Securities 2024 Health Care Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings Call Transcript: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Quarterly report: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings release: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Slides: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 2, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 26, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 4, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Feb 28, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Annual report: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings release: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Slides: Q4 2023

Feb 26, 2024, 8:00 AM EST - 2 years ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 8, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 7, 2024, 10:00 AM EST - 2 years ago

Krystal Biotech Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 4, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Dec 19, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Nov 27, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Nov 15, 2023, 11:30 AM EST - 2 years ago

Krystal Biotech Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Quarterly report: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Cutlass Jun. 22 at 12:50 PM

$KRYS Ahh the good old days in the 30's and 40's - I sold out awhile back - 💥

0 · Reply

Florestan Jun. 21 at 2:39 AM

$KRYS the king of gene therapy. Undisputed.

0 · Reply

WAJeff Jun. 18 at 6:42 PM

$KRYS $356.50 ath

0 · Reply

LewisDaKat Jun. 18 at 10:30 AM

0 · Reply

WAJeff Jun. 17 at 3:17 PM

$KRYS $340.79 ath

0 · Reply

SwingTraderPro1 Jun. 11 at 10:26 PM

0 · Reply

WAJeff Jun. 11 at 4:05 PM

$KRYS $325 ath

0 · Reply

ZManicItalian Jun. 9 at 9:29 PM

$KRYS

0 · Reply

Shlobby May. 14 at 2:10 PM

Long $KRYS

0 · Reply

CapitalMonk May. 13 at 4:25 AM

0 · Reply

MorganHoratio May. 11 at 9:32 PM

Today, all of these stocks hit all-time highs at some point. Arrow Electronics $ARW Powell Industries $POWL Synnex $SNX Krystal Biotech $KRYS Enersys $ENS Today’s ATH list is a perfect showcase of a "Multi-Sector Breakout" across AI infra, Life Sciences, and Supply Chain! 🚀 As of May 11, 2026, $POWL hitting $328 reaffirms its dominance in power distribution. $ARW crossing $202 and $ENS breaking $236 highlight the massive recovery in AI hardware distribution and energy storage. Notably, $KRYS tapping $315 marks a pivotal re-rating for the biotech sector. The takeaway: 2026’s wealth effect is flowing beyond GPUs into "Power, Distribution, and Deep-Tech Bio." Which of these "non-GPU" leaders do you think has the most room to run? Let’s discuss your 2026 strategy below!

1 · Reply

ZManicItalian May. 11 at 2:02 PM

$KRYS 🍻🐂

0 · Reply

Doozio May. 9 at 12:57 AM

$KRYS ONTO 🐒🍌🧠⏰♾️

0 · Reply

trichomy May. 7 at 1:43 PM

$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!

0 · Reply

trichomy May. 6 at 4:40 PM

$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥

2 · Reply

Synaptric May. 6 at 1:35 PM

Narrow-tech-only-market angst? Check out 52-week highs in Healthcare $ARWR $CYTK $JAZZ $BTSG $KRYS

0 · Reply

trichomy May. 5 at 9:38 PM

$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html

1 · Reply

VAK7 May. 5 at 3:36 AM

$HOOD $KRYS $NBIS $RCUS $TGTX That was a very nice summary. And picks. And set me up for 75% 1 yeah performance since 5/4/25. TGTX and HOOD are lagging from this cohort of 5. But not for long. Imho TGTX will be over $45 this year; and HOOD will be in triple digits, no doubt about it. I could have done better, but, to my defense, MW should have sold TGTX before summer 2025; I told myself that if he does not do that, or buy out EU rights, i will reduce my TGTX position before 2 year term to buyback EU rights lapses. And I did not. Price you pay for your own indecisiveness.

0 · Reply

1986iamwallstreet May. 4 at 1:49 PM

$KRYS dips bought about to take off

0 · Reply

StocktwitsEarnings May. 4 at 11:11 AM

$KRYS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $1.91 up 54.03% YoY • Reported revenue of $116.36M up 31.95% YoY

0 · Reply

1986iamwallstreet May. 4 at 11:04 AM

$KRYS Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate

0 · Reply

1986iamwallstreet May. 1 at 2:10 PM

$KRYS another one that can get bought out

0 · Reply

Market Cap	10.12B
Revenue (ttm)	389.13M
Net Income (ttm)	204.83M
EPS (ttm)	N/A
PE Ratio	45.91
Forward PE	43.86
Profit Margin	52.64%
Debt to Equity Ratio	0.00

Volume	378,400
Avg Vol	302,138
Day's Range	N/A - N/A
Shares Out	29.48M
Stochastic %K	65%
Beta	0.53
Analysts	Strong Sell
Price Target	$347.44